Skip to main content

Table 4 Meta-analysis of PubMed listed studies about PD-L1 immunohistochemistry in cholangiocarcinoma

From: Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies

Study n= Subtype PD-L1 clone Inflammatory cells, n/n (%) Tumor cells, n/n (%) Cut-off Evaluation criteria
Ye et al., 2009 31 iCCA 28–8 n.a. 31/31 (100) H-scorea, no cut-off described cytoplasmatic + membranous
Gani et al., 2016 54 iCCA 5H1 31/54 (57) 39/54 (72) % positive cells (> 5%) membranous
Sabbatino et al., 2016 27 iCCA 22C3 27/27 (100) 8/27 (30) H-scorea (> 25) membranous
Sato et al., 2017 68 iCCA, eCCA 28–8 n.a. 1/23 (4)
4/45 (8)
% positive cells (< 5, > 5, > 10%) n.a.
Ma et al., 2017 70 eCCA EPR1161 37/70 (53) 30/70 (43) Immunohistochemical Score*: > 3 cytoplasmatic + membranous
Fontugne et al., 2017 99 iCCA,
pCCA
E1L3N 31/58 (53)
15/41 (37)
5/58 (9)
4/41 (9)
Strong staining in > 5% of tumor cells membranous
Sangkhamanon et al., 2017 46 n.a. 5H1 n.a. 32/46 (70) > 1% positive tumor cells membranous
Walter et al., 2017 69 pCCA
dCCA
E1L3N 12/40 (30)
9/29 (31)
4/40 (10)
4/29 (14)
H-scorea (> 3) membranous
  1. dCCA distal cholangiocarcinoma, eCCA extrahepatic cholangiocarcinoma, iCCA intrahepatic cholangiocarcinoma, pCCA perihilar cholangiocarcinoma.a Immunohistochemical scoring system: percentage of cells with weak staining × 1 + percentage of cells with moderate staining × 2 + percentage of cells with strong staining × 3 = H-Score *Immunohistochemical scoring system: Stained cells (0:< 5%,1:5–25%, 2:26–50%,3:> 50%) x intensity (1+, 2+, 3+) , n.a., not available
\